Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study [Corrigendum]
Authors Dahl R, Jadayel D, Alagappan V, Chen H, Banerji D
Received 1 November 2013
Accepted for publication 1 November 2013
Published 16 January 2014 Volume 2014:9(1) Pages 85—86
Dahl R, Jadayel D, Alagappan VKT, Chen H, Banerji D. Int J Chron Obstruct Pulmon Dis. 2013;8:501–508.
On page 501, note that in the Results section of the Abstract, the sentence "Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.46 L ± 0.02 and 1.46 L ± 0.18, respectively." should read "Trough FEV1 at week 4 for QVA149 and IND+GLY was 1.5 L ± 0.02."
On page 505, note that the sentence "The least squares mean ± standard error (LSM ± SE) trough FEV1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 and 1.5 L ± 0.18, respectively (Figure 3)." should read "The least squares mean ± standard error (LSM ± SE) trough FEV1 at week 4 for QVA149 and for the free-dose combination of IND+GLY was 1.5 L ± 0.02 (Figure 3)."
On page 505, note that the confidence interval for Figure 3 was incorrect, and the confidence intervals and y-axis for Figure 4 were also incorrect. The full and correct figures are given here.
Read the original article
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]